Research Article

Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China

Yao Xu,1,2 Haixiao Wu,1,2 Guijun Xu,2,3 Zhuming Yin,1 Xin Wang,2,4 Vladimir P. Chekhonin,2,5 Karl Peltzer,2,6 Shu Li,2 Huiyang Li,2 Jin Zhang,1,2 Wenjuan Ma,1,2 and Chao Zhang1,2

1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
2The Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China
3Department of Orthopedics, Tianjin Hospital, Tianjin University, Tianjin, China
4Department of Health Management Center (Epidemiology and Biostatistics), First Affiliated Hospital, Army Medical University, Chongqing, China
5Department of Basic and Applied Neurobiology, Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia
6Department of Psychology, University of the Free State, Turffontein, South Africa

Correspondence should be addressed to Wenjuan Ma; mawenjuan2008@163.com and Chao Zhang; drzhangchao@tmu.edu.cn

Received 20 October 2021; Accepted 23 November 2021; Published 31 January 2022

Academic Editor: Sharad Goyal

Copyright © 2022 Yao Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Bone metastasis in breast cancer remains globally concerned. Accurate survival estimation would be beneficial for clinical decision-making, especially for the patients with potential indications of surgery. Based on a retrospective cohort from China, the study aimed to construct a prognostic prediction nomogram for breast cancer patients with bone metastasis. Methods. Breast cancer patients with bone metastasis diagnosed between 2009 and 2017 in our department were retrospectively selected. The total cohort was divided into construction and validation cohorts (ratio 7:3). A nomogram was constructed to predict the probability of survival, and the performance of model was validated. Results. A total of 343 patients were enrolled with 243 and 100 patients in construction and validation cohorts, respectively. The median overall survival for the total cohort was 63.2 (95% CI: 52.4–74.0) months. Elevated ALP (HR = 1.71, 95% CI: 1.16–2.51; \( P = 0.006 \)), no surgery for breast cancer (HR = 2.19, 95% CI: 1.30–3.70; \( P = 0.003 \)), synchronous bone metastasis (HR = 1.98, 95% CI: 1.22–3.22; \( P = 0.006 \)), and liver metastasis (HR = 1.68, 95% CI: 1.20–2.37; \( P = 0.003 \)) were independent prognostic factors for worse survival. The independent predictors and other five factors (including age at diagnosis, ER status, PR status, Her-2 status, and the performance of bisphosphonate) were incorporated to construct the nomogram. The C-index was 0.714 (95% CI: 0.636–0.792) and 0.705 (95% CI: 0.705) in the construction cohort and validation cohort, respectively. All the calibration curves were close to the 45-degree line, which indicated satisfactory calibration. Conclusion. A retrospective study aiming at prognostic estimation of breast cancer patients with bone metastasis was designed. Four independent prognostic factors were identified and a prognostic nomogram was constructed with satisfactory discrimination and calibration. The model could be used in survival estimation and individualized treatment planning.
1. Introduction

Breast cancer (BC) is the most common primary malignant tumor in female. In 2021, there will be 281,550 estimated new cases and 43,600 estimated deaths in the United States [1]. Due to the developed early detection and comprehensive treatment strategies, the prognosis of BC has been improved in recent years [2, 3]. Despite of the improved prognosis of patients at early stage, metastatic breast cancer (MBC) attributed to the main cause of death among BC patients and it was reported that the 5-year breast cancer-specific survival (BCSS) was dismal 26% [4]. Compared with other MBC patients, the survival of patients with breast cancer bone metastasis (BCBM) was better. The median survival of patients with bone-only metastasis was up to 24–54 months [5, 6]. Due to the high heterogeneity of BC, identification of prognostic factors and prediction of survival time was the prerequisite for individual decision-making.

Except the Department of Breast Cancer, bone metastasis in breast cancer was a common disease in the Department of Bone and Soft Tissue Tumor. Such patients usually chose the Department of Bone and Soft Tissue Tumor for skeletal-related events (SREs) or/and motor dysfunction. Compared with other departments, the patients with synchronous bone metastasis (SBM) are more common. The patients usually require the surgical intervention to release the symptom. Prognostic estimation was one of the most important issues before surgery performance.

Several prognostic factors of BCBM patients have been investigated in previous studies. A retrospective study on 238 cases concluded that breast subtype was associated with overall survival (OS), bone disease-free survival, and survival with bone disease [7]. The 5-year survival rate was up to 40% for luminal A, luminal B, and basal patients, while it was 4% for triple negative breast cancer patients [7]. Another study based on Surveillance, Epidemiology, and End Results (SEER) dataset attested that breast subtype, age at diagnosis, race, tumor grade, and the presence of organ metastasis were independent prognostic factors of BCBM patients [8]. Sufficient literatures on prognostic factors were reported, which was fundamental for subsequent study on survival estimation [9-12].

Clinical prediction models, usually incorporating patients’ demographic and clinical characteristics, were an efficient tool to evaluate the probability of disease development and survival outcome [13, 14]. As one of the most widespread predictive models, nomogram was widely reported in several types of cancers [15-17]. However, most prognostic nomograms among MBC patients were constructed based on SEER database [18, 19]. The generalizability in Chinese population remained unclear. Thus, the present study aimed to construct a prognostic prediction nomogram based on the cohort from the Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. The nomogram can help oncologists estimate prognosis accurately and guide the individualize treatment for Chinese patients.

2. Materials and Methods

2.1. Data Source and Cohort Selection. The medical records of breast cancer bone metastasis (BCBM) patients in the Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, were retrospectively collected. All of patients were older than 18 and diagnosed between January 2009 and December 2017. The exclusion criteria were as follows: (1) patients diagnosed with secondary primary cancer or multiple primary cancers; (2) patients diagnosed with bilateral primary breast cancer; (3) male patients; (4) foreign patients; (5) patients without detailed medical records; (6) patients without follow-up status; (7) patients with metabolic bone disease; and (8) patients with severe osteoporosis. The flowchart of the patient selection is listed in Figure 1.

2.2. Demographic and Clinical Variables. Patients’ demographic and clinical characteristics were included as follows: age at diagnosis (18-45 years, 46-55 years, or >55 years), marital status (married or unmarried), history of smoking (yes or no), alcohol consumption (yes or no), menstrual status (menstruation or menopause), history of abortion (no or yes), family history of cancer (yes or no), histological type (ductal carcinoma or others), tumor grade (Grade I-II or Grade III), tumor size (<2 cm, 2-5 cm, or >5 cm), lymph node metastasis (yes or no), ER status (positive or negative), PR status (positive or negative), Her-2 status (positive or negative), Ki-67 status (positive or negative), performance of surgery (yes or no), chemotherapy (yes or no), radiotherapy (yes or no), endocrinotherapy (yes or no), and targeted therapy (yes or no). The chemotherapy regimens included AC, CAF, and TAC in the present study.

Laboratory data were investigated and grouped according to normal threshold value in our hospital, including hemoglobin (HGB: 115-150 g/L, <115 g/L, or >150 g/L), carbohydrate antigen (CA153: 0-25 U/ml or >25 U/ml), carcinoembryonic antigen (CEA: 0-5 ng/ml or >5 ng/ml), alkaline phosphatase (ALP: 50-135 U/L, <50 U/L, or >135 U/L), and serum calcium (2.10-2.55 mmol/L, <2.10 mmol/L, or >2.55 mmol/L). ABO blood type was also investigated, being grouped into A type, B type, AB type, and O type.

The records on organ metastasis, skeletal-related events (SREs), and associated treatment were included: the radiotherapy for bone metastatic site (no or yes), pathological fracture (no or yes), spinal cord compression (no or yes), surgery for bone metastatic site (no or yes), performance of bisphosphonate therapy (no or yes), liver metastasis (no or yes), brain metastasis (no or yes), lung metastasis (no or yes), and other organs metastasis (no or yes). As in previous study, synchronous bone metastasis (SBM) was defined as BM diagnosis within 6 months after BC diagnosis, while metachronous bone metastasis (MBM) was defined as BM diagnosis more than 6 months after BC diagnosis [20, 21].

2.3. Statistical Analysis. All missing values in the current study were completed by multiple imputation methods. The total cohort was randomly divided into the construction and
Breast cancer patients with bone metastasis diagnosed between January 2009 and December 2017 (N=647)

- Excluded Patients diagnosed with secondary primary cancer or multiple primary cancers (N=15)
- Excluded Patients diagnosed with bilateral primary breast cancer (N=8)
- Excluded Gender male (N=1)
- Excluded Foreign patients (N=3)
- Excluded Patients without detailed medical records (N=19)
- Excluded Patients without follow-up status (N=258)

Total cohort (N=343)

Construction cohort (N=243)  Validation cohort (N=100)

Figure 1: The flowchart of the patient selection.

The Breast Journal

2.4. Ethical Statement. The present study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, and the Research Ethics Board of the Tianjin Medical University Cancer Institute and Hospital approved the study (bc2021010).

3. Results

3.1. Demographic and Clinicopathologic Characteristics. A total of 343 patients were eventually selected in the present study. After random grouping of the total cohort, there were 243 and 100 cases in the construction cohort and validation cohort, respectively.

For the total cohort, the median age was 48.0 (interquartile range, IQR: 41.0–57.0) years and patients with age ≤45 years, 46–55 years, and >55 years accounted for 39.1%, 31.8%, and 29.2%, respectively. The majority of patients were married (N=324, 94.5%). Most of the tumors were 2–5 cm (N=175, 51.0%) and with positive nodal status (N=276, 80.5%). The tumor grade was I-II and III in 69.4% (N=238) and 30.6% (N=105) of the patients. The percentages of patients with ER, PR, Her-2, and Ki-67 positive status were 69.1% (N=237), 56.6% (N=194), 21.6% (N=74), and 25.4% (N=87), respectively. Distant metastasis was found among 119 patients in the liver, 36 patients in the brain, 137 patients in the lung, and 76 patients in other organs. More detailed information about demographic and clinicopathologic characteristics of the construction cohort and validation cohort is shown in Table 1.

3.2. Synchronous Bone Metastasis and Metachronous Bone Metastasis. According to previous definition, there were 148 SBM patients and 195 MBM patients. The distribution of survival outcome of SBM and MBM patients is shown in Figure 2(a). For MBM patients, the mean interval between the diagnosis of breast cancer and bone metastasis was 61.9 (6.2–225.2) months. The cumulative frequency is shown in Figure 2(b).

For SBM patients, 95.9% (142/148) presented axial skeleton (including the skull and vertebrae) metastasis while 46.6% (69/148) presented appendicular skeleton metastasis. The number of patients with axial skeleton and appendicular skeleton metastasis were 192 (98.5%) and 98 (50.3%) in MBM patients.

3.3. Survival and Prognostic Factors of Breast Cancer Patients with BM. At the last follow-up, a total of 273 patients deceased. The mean OS was 86.3 (95% CI: 77.1–95.6) months and the median OS was 63.2 (95% CI: 52.4–74.0) months. The 1-, 2-, 5-, and 10-year survival rates were 88.9%, 69.3%, 52.8%, and 25.8%, respectively.

In the construction cohort, a total of 190 patients died at the last follow-up. The mean OS and the median OS were 92.8 (95% CI: 80.7–104.9) and 70.0 (95% CI: 59.2–80.8) months, respectively. The 1-, 2-, 5-, and 10-year survival rates were 90.5%, 71.9%, 56.3%, and 27.3%, respectively. The following variables were associated with survival: age at diagnosis, ABO blood type, CA153, ALP, tumor grade,
| Subject characteristics | Total cohort | Construction cohort | Validation cohort | $\chi^2$ | $P$ value |
|-------------------------|-------------|---------------------|------------------|--------|-----------|
| **Age**                 |             |                     |                  |        |           |
| 18–45                   | 134 (39.1)  | 98 (40.3)           | 36 (36.0)        | 0.594  | 0.743     |
| 46–55                   | 109 (31.8)  | 75 (30.9)           | 34 (34.0)        |        |           |
| >55                     | 100 (29.2)  | 70 (28.8)           | 30 (30.0)        |        |           |
| **Marital status**      |             |                     |                  |        |           |
| Married                 | 324 (94.5)  | 228 (93.8)          | 96 (96.0)        | 0.639  | 0.424     |
| Unmarried               | 19 (5.5)    | 15 (6.2)            | 4 (4.0)          |        |           |
| **History of smoking**  |             |                     |                  |        |           |
| Yes                     | 17 (5.0)    | 11 (4.5)            | 6 (6.0)          | 0.326  | 0.568     |
| No                      | 326 (95.0)  | 232 (95.5)          | 94 (94.0)        |        |           |
| **Alcohol consumption** |             |                     |                  |        |           |
| Yes                     | 14 (4.1)    | 12 (4.9)            | 2 (2.0)          | 1.562  | 0.211     |
| No                      | 329 (95.9)  | 231 (95.1)          | 98 (98.0)        |        |           |
| **Menstrual status**    |             |                     |                  |        |           |
| Menstruation            | 108 (31.5)  | 80 (32.9)           | 28 (28.0)        | 0.796  | 0.372     |
| Menopause               | 235 (68.5)  | 163 (67.1)          | 72 (72.0)        |        |           |
| **History of abortion** |             |                     |                  |        |           |
| No                      | 236 (68.8)  | 162 (66.7)          | 74 (74.0)        | 1.775  | 0.183     |
| Yes                     | 107 (31.2)  | 81 (33.3)           | 26 (26.0)        |        |           |
| **Family history of tumor** |       |                     |                  |        |           |
| Yes                     | 83 (24.2)   | 61 (25.1)           | 22 (22.0)        | 0.372  | 0.542     |
| No                      | 260 (75.8)  | 182 (74.9)          | 78 (78.0)        |        |           |
| **ABO blood type**      |             |                     |                  |        |           |
| A type                  | 90 (26.2)   | 66 (27.2)           | 24 (24.0)        |        |           |
| B type                  | 116 (33.8)  | 82 (33.7)           | 34 (34.0)        | 0.549  | 0.908     |
| AB type                 | 46 (13.4)   | 31 (12.8)           | 15 (15.0)        |        |           |
| O type                  | 91 (26.5)   | 64 (26.3)           | 27 (27.0)        |        |           |
| **HGB**                 |             |                     |                  |        |           |
| 115–150 g/L             | 276 (80.5)  | 194 (79.8)          | 82 (82.0)        | 0.227  | 0.893     |
| <115 g/L                | 59 (17.2)   | 43 (17.7)           | 16 (16.0)        |        |           |
| >150 g/L                | 8 (2.3)     | 6 (2.5)             | 2 (2.0)          |        |           |
| **CA153**               |             |                     |                  |        |           |
| 0–25 U/ml               | 113 (32.9)  | 75 (30.9)           | 38 (38.0)        | 1.633  | 0.201     |
| >25 U/ml                | 230 (67.1)  | 168 (69.1)          | 62 (62.0)        |        |           |
| **CEA**                 |             |                     |                  |        |           |
| 0–5 ng/ml               | 171 (49.9)  | 116 (47.7)          | 55 (55.0)        | 1.495  | 0.221     |
| >5 ng/ml                | 172 (50.1)  | 127 (52.3)          | 45 (45.0)        |        |           |
| **ALP**                 |             |                     |                  |        |           |
| 50–135 U/L              | 227 (66.2)  | 164 (67.5)          | 63 (63.0)        | 0.659  | 0.719     |
| <50 U/L                 | 26 (7.6)    | 18 (7.4)            | 8 (8.0)          |        |           |
| >135 U/L                | 90 (26.2)   | 61 (25.1)           | 29 (29.0)        |        |           |
| **Serum calcium**       |             |                     |                  |        |           |
| 2.10–2.55 mmol/L        | 228 (66.5)  | 165 (67.9)          | 63 (63.0)        | 1.050  | 0.592     |
| <2.10 mmol/L            | 38 (11.1)   | 27 (11.1)           | 11 (11.0)        |        |           |
| >2.55 mmol/L            | 77 (22.4)   | 51 (21.0)           | 26 (26.0)        |        |           |
| **Pathology**           |             |                     |                  |        |           |
| Ductal carcinoma        | 219 (63.8)  | 155 (63.8)          | 64 (64.0)        | 0.001  | 0.970     |
| Others                  | 124 (36.2)  | 88 (36.2)           | 36 (36.0)        |        |           |
| **Grade**               |             |                     |                  |        |           |
| I–II                    | 238 (69.4)  | 172 (70.8)          | 66 (66.0)        | 0.763  | 0.382     |
| III                     | 105 (30.6)  | 71 (29.2)           | 34 (34.0)        |        |           |
| **Tumor size**          |             |                     |                  |        |           |
| <2 cm                   | 123 (35.9)  | 80 (32.9)           | 43 (43.0)        | 3.187  | 0.203     |
| 2–5 cm                  | 175 (51.0)  | 129 (53.1)          | 46 (46.0)        |        |           |
| >5 cm                   | 45 (13.1)   | 34 (14)             | 11 (11.0)        |        |           |
| Subject characteristics            | Total cohort | Construction cohort | Validation cohort | $\chi^2$ | P value |
|------------------------------------|--------------|---------------------|-------------------|---------|---------|
|                                    | N (%)        | N (%)               | N (%)             |         |         |
| **Lymph node metastasis**          |              |                     |                   |         |         |
| Yes                                | 276 (80.5)   | 198 (81.5)          | 78 (78.0)         | 0.546   | 0.460   |
| No                                 | 67 (19.5)    | 45 (18.5)           | 22 (22.0)         |         |         |
| **ER status**                      |              |                     |                   |         |         |
| Positive                           | 237 (69.1)   | 165 (67.9)          | 72 (72.0)         | 0.557   | 0.455   |
| Negative                           | 106 (30.9)   | 78 (32.1)           | 28 (28.0)         |         |         |
| **PR status**                      |              |                     |                   |         |         |
| Positive                           | 194 (56.6)   | 134 (55.1)          | 60 (60.0)         | 0.680   | 0.410   |
| Negative                           | 149 (43.4)   | 109 (44.9)          | 40 (40.0)         |         |         |
| **Her-2 status**                   |              |                     |                   |         |         |
| Positive                           | 74 (21.6)    | 51 (21.0)           | 23 (23.0)         | 0.170   | 0.681   |
| Negative                           | 269 (78.4)   | 192 (79.0)          | 77 (77.0)         |         |         |
| **Ki-67 status**                   |              |                     |                   |         |         |
| Positive                           | 87 (25.4)    | 60 (24.7)           | 27 (27.0)         | 0.199   | 0.655   |
| Negative                           | 256 (74.6)   | 183 (75.3)          | 73 (73.0)         |         |         |
| **Surgery for BC**                 |              |                     |                   |         |         |
| Yes                                | 262 (76.4)   | 186 (76.5)          | 76 (76.0)         | 0.012   | 0.914   |
| No                                 | 81 (23.6)    | 57 (23.5)           | 24 (24.0)         |         |         |
| **Chemotherapy**                   |              |                     |                   |         |         |
| No                                 | 21 (6.1)     | 11 (4.5)            | 10 (10.0)         | 3.692   | 0.055   |
| Yes                                | 322 (93.9)   | 232 (95.5)          | 90 (90.0)         |         |         |
| **Radiotherapy**                   |              |                     |                   |         |         |
| No                                 | 225 (65.6)   | 160 (65.8)          | 65 (65.0)         | 0.022   | 0.881   |
| Yes                                | 118 (34.4)   | 83 (34.2)           | 35 (35.0)         |         |         |
| **Endocrinotherapy**               |              |                     |                   |         |         |
| No                                 | 183 (53.4)   | 129 (53.1)          | 54 (54.0)         | 0.024   | 0.878   |
| Yes                                | 160 (46.6)   | 114 (46.9)          | 46 (46.0)         |         |         |
| **Targeted therapy**               |              |                     |                   |         |         |
| No                                 | 302 (88.0)   | 212 (87.2)          | 90 (90.0)         | 0.512   | 0.474   |
| Yes                                | 41 (12.0)    | 31 (12.8)           | 10 (10.0)         |         |         |
| **Time of BM**                     |              |                     |                   |         |         |
| SBM                                | 148 (43.1)   | 104 (42.8)          | 44 (44.0)         | 0.042   | 0.838   |
| MBM                                | 195 (56.9)   | 139 (57.2)          | 56 (56.0)         |         |         |
| **Radiotherapy for BM**            |              |                     |                   |         |         |
| No                                 | 283 (82.5)   | 202 (83.1)          | 81 (81.0)         | 0.222   | 0.637   |
| Yes                                | 60 (17.5)    | 41 (16.9)           | 19 (19.0)         |         |         |
| **Pathological fracture**          |              |                     |                   |         |         |
| No                                 | 310 (90.4)   | 222 (91.4)          | 88 (88.0)         | 0.919   | 0.338   |
| Yes                                | 33 (9.6)     | 21 (8.6)            | 12 (12.0)         |         |         |
| **Spinal cord compression**        |              |                     |                   |         |         |
| No                                 | 333 (97.1)   | 236 (97.1)          | 97 (97.0)         | 0.004   | 0.952   |
| Yes                                | 10 (2.9)     | 7 (2.9)             | 3 (3.0)           |         |         |
| **Surgery for BM**                 |              |                     |                   |         |         |
| No                                 | 334 (97.4)   | 237 (97.5)          | 97 (97.0)         | 0.078   | 0.780   |
| Yes                                | 9 (2.6)      | 6 (2.5)             | 3 (3.0)           |         |         |
| **Performance of BPs**             |              |                     |                   |         |         |
| No                                 | 84 (24.5)    | 56 (23.0)           | 28 (28.0)         | 0.941   | 0.332   |
| Yes                                | 259 (75.5)   | 187 (77.0)          | 72 (72.0)         |         |         |
| **Liver metastasis**               |              |                     |                   |         |         |
| No                                 | 224 (65.3)   | 155 (63.8)          | 69 (69.0)         | 0.850   | 0.357   |
| Yes                                | 119 (34.7)   | 88 (36.2)           | 31 (31.0)         |         |         |
| **Brain metastasis**               |              |                     |                   |         |         |
| No                                 | 307 (89.5)   | 217 (89.3)          | 90 (90.0)         | 0.037   | 0.848   |
| Yes                                | 36 (10.5)    | 26 (10.7)           | 10 (10.0)         |         |         |
lymph node metastasis, ER status, PR status, Her-2 status, Ki-67 status, surgery for BC, chemotherapy, endocrinotherapy, SBM/MBM, performance of BPs, liver metastasis, lung metastasis, and other organs metastasis. After adjusting all these characteristics in multivariate analysis, elevated ALP (HR $= 1.71$, 95% CI: $1.16$–$2.51$; $P = 0.006$), no surgery for breast cancer (HR $= 2.19$, 95% CI: $1.30$–$3.70$; $P = 0.003$), SBM (HR $= 1.98$, 95% CI: $1.22$–$3.22$; $P = 0.006$), and liver metastasis (HR $= 1.68$, 95% CI: $1.20$–$2.37$; $P = 0.003$) were independent prognostic factors for worse survival. More details about the univariate and multivariate Cox regression analysis are shown in Tables 2 and 3, respectively.

### Table 1: Continued.

| Subject characteristics | Total cohort N (%) | Construction cohort N (%) | Validation cohort N (%) | $\chi^2$ | $P$ value |
|-------------------------|--------------------|---------------------------|-------------------------|---------|-----------|
| **Lung metastasis**     |                    |                           |                         |         |           |
| No                      | 206 (60.1)         | 147 (60.5)                | 59 (59.0)               | 0.066   | 0.797     |
| Yes                     | 137 (39.9)         | 96 (39.5)                 | 41 (41.0)               |          |           |
| **Other organs metastasis** |                 |                           |                         |         |           |
| No                      | 267 (77.8)         | 191 (78.6)                | 76 (76.0)               | 0.278   | 0.598     |
| Yes                     | 76 (22.2)          | 52 (21.4)                 | 24 (24.0)               |          |           |

HGB: hemoglobin; CA153: carbohydrate antigen 153; CEA: carcinoembryonic antigen; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.

3.4. **Construction and Validation of Nomogram.** As shown in Figure 3, the abovementioned four independent prognostic factors and other five factors (including age at diagnosis, ER status, PR status, Her-2 status, and the performance of BPs) were included to construct a prognostic nomogram. The C-index was 0.714 (95% CI: 0.636–0.792) and the AUC of the nomogram for 1 year, 3 years, 5 years, and 10 years were 0.910, 0.848, 0.765, and 0.752, respectively (Figure 4). The calibration curve revealed good agreement between the predicted and observed probabilities. All the calibration curves were close to the 45-degree line (Figure 5).

In the validation cohort, the nomogram showed satisfactory strength of discrimination. The C-index was 0.705 (95% CI: 0.705) and the AUC for 1 year, 3 years, 5 years, and 10 years were 0.831, 0.766, 0.689, and 0.696, respectively (Figure 6). Excellent ability of calibration was achieved with all calibration curves close to the 45-degree line (Figure 7).

### Discussion

In the current study, a Chinese breast cancer bone metastasis cohort from the Department of Bone and Soft Tissue Tumor was described and associated prognostic factors were identified. Unlike cohorts based on the public dataset, our cohort comprised more treatment information and laboratory data. Besides, SBM and MBM were distinguished according to the time of BM. Previous studies demonstrated the impact of these variables on prognosis prediction and our study further confirmed that [19–23]. Meanwhile, these variables were incorporated to construct a predictive nomogram with satisfactory discrimination and calibration.
Table 2: Univariate Cox proportional hazard regression model for analyzing associated factors in the construction cohort.

| Subject characteristics | B     | SE    | Wald  | \( P \) value | HR    | HR 95% CI |
|-------------------------|-------|-------|-------|--------------|-------|----------|
| **Age**                 |       |       |       |              |       |          |
| 18–45                   | 0.169 | 0.176 | 0.916 | 0.338        | 1.18  | 0.84–1.67 |
| 46–55                   | 0.590 | 0.180 | 10.675| 0.001        | 1.80  | 1.27–2.57 |
| >55                     | 0.169 | 0.176 | 0.916 | 0.338        | 1.18  | 0.84–1.67 |
| **Marital status**      |       |       |       |              |       |          |
| Married                 | 0.230 | 0.343 | 0.449 | 0.503        | 1.26  | 0.64–2.46 |
| Unmarried               | 0.172 | 0.342 | 0.224 | 0.636        | 1.19  | 0.58–2.43 |
| **History of smoking**  |       |       |       |              |       |          |
| Yes                     | 0.182 | 0.342 | 0.281 | 0.596        | 1.20  | 0.61–2.35 |
| No                      | 0.010 | 0.157 | 0.004 | 0.952        | 1.01  | 0.74–1.38 |
| **Alcohol consumption** |       |       |       |              |       |          |
| Yes                     | 0.092 | 0.188 | 0.240 | 0.624        | 1.10  | 0.76–1.59 |
| No                      | 0.558 | 0.235 | 5.656 | 0.017        | 1.75  | 1.10–2.77 |
| **Menstrual status**    |       |       |       |              |       |          |
| Menstruation            | –0.211| 0.161 | 1.717 | 0.190        | 0.81  | 0.59–1.11 |
| Menopause               | 0.010 | 0.157 | 0.004 | 0.952        | 1.01  | 0.74–1.38 |
| **History of abortion** |       |       |       |              |       |          |
| Yes                     | –0.079| 0.171 | 0.212 | 0.645        | 0.92  | 0.66–1.29 |
| No                      | 0.016 | 0.176 | 0.002 | 0.974        | 1.01  | 0.74–1.38 |
| **Family history of tumor** |       |       |       |              |       |          |
| Yes                     | 0.092 | 0.188 | 0.240 | 0.624        | 1.10  | 0.76–1.59 |
| No                      | 0.558 | 0.235 | 5.656 | 0.017        | 1.75  | 1.10–2.77 |
| **ABO blood type**      |       |       |       |              |       |          |
| A type                  | 0.212 | 0.171 | 0.212 | 0.645        | 0.92  | 0.66–1.29 |
| B type                  | –0.079| 0.171 | 0.002 | 0.974        | 1.01  | 0.74–1.38 |
| AB type                 | 0.182 | 0.342 | 0.281 | 0.596        | 1.20  | 0.61–2.35 |
| O type                  | 0.002 | 0.204 | 0.002 | 0.994        | 1.00  | 0.67–1.49 |
| **HGB**                 |       |       |       |              |       |          |
| 115–150g/L              | 0.098 | 0.193 | 0.258 | 0.611        | 1.10  | 0.76–1.61 |
| <115g/L                 | 0.758 | 0.457 | 2.758 | 0.097        | 2.14  | 0.87–5.22 |
| >150g/L                 |       |       |       |              |       |          |
| **CA153**               |       |       |       |              |       |          |
| 0–25 U/ml               | –0.342| 0.158 | 4.684 | 0.030        | 0.71  | 0.52–0.97 |
| >25 U/ml                |       |       |       |              |       |          |
| **CEA**                 |       |       |       |              |       |          |
| 0–5 ng/ml               | –0.142| 0.146 | 0.946 | 0.331        | 0.87  | 0.65–1.16 |
| >5 ng/ml                |       |       |       |              |       |          |
| **ALP**                 |       |       |       |              |       |          |
| 50–135 U/L              | 0.451 | 0.166 | 7.373 | 0.007        | 1.57  | 1.13–2.18 |
| <50 U/L                 | 0.118 | 0.267 | 0.197 | 0.657        | 1.13  | 0.67–1.90 |
| >135 U/L                |       |       |       |              |       |          |
| **Serum calcium**       |       |       |       |              |       |          |
| 2.10–2.55 mmol/L        | 0.185 | 0.232 | 0.636 | 0.425        | 1.20  | 0.76–1.89 |
| <2.10 mmol/L            | 0.207 | 0.185 | 1.251 | 0.263        | 1.23  | 0.86–1.77 |
| >2.55 mmol/L            |       |       |       |              |       |          |
| **Pathology**           |       |       |       |              |       |          |
| Ductal carcinoma        | 0.227 | 0.152 | 2.240 | 0.134        | 1.26  | 0.93–1.69 |
| Others                  | 0.470 | 0.160 | 8.654 | 0.003        | 1.60  | 1.17–2.19 |
| **Grade**               |       |       |       |              |       |          |
| I-II                    | 0.073 | 0.165 | 0.196 | 0.658        | 1.08  | 0.78–1.49 |
| III                     | 0.214 | 0.238 | 0.814 | 0.367        | 1.24  | 0.78–1.97 |
| **Tumor size**          |       |       |       |              |       |          |
| <2 cm                   |       |       |       |              |       |          |
| 2–5 cm                  |       |       |       |              |       |          |
| >5 cm                   |       |       |       |              |       |          |
| **Lymph node metastasis** |       |       |       |              |       |          |
| Yes                     |       |       |       |              |       |          |
| No                      | –0.459| 0.191 | 5.766 | 0.016        | 0.63  | 0.44–0.92 |
| **Tumor size**          |       |       |       |              |       |          |
| <2 cm                   |       |       |       |              |       |          |
| 2–5 cm                  |       |       |       |              |       |          |
| >5 cm                   |       |       |       |              |       |          |
| **Lymph node metastasis** |       |       |       |              |       |          |
| Yes                     |       |       |       |              |       |          |
| No                      | –0.459| 0.191 | 5.766 | 0.016        | 0.63  | 0.44–0.92 |

The Breast Journal
Table 2: Continued.

| Subject characteristics          | B     | SE    | Wald    | P value | HR    | HR 95% CI       |
|----------------------------------|-------|-------|---------|---------|-------|-----------------|
| ER status                        |       |       |         |         |       |                 |
| Positive                         | 1.00  |       |         |         |       |                 |
| Negative                         | 0.330 | 0.154 | 4.615   | 0.032  | 1.39  | 1.03–1.88       |
| PR status                        |       |       |         |         |       |                 |
| Positive                         | 1.00  |       |         |         |       |                 |
| Negative                         | 0.396 | 0.146 | 7.390   | 0.007  | 1.49  | 1.12–1.98       |
| Her-2 status                     |       |       |         |         |       |                 |
| Positive                         | 1.00  |       |         |         |       |                 |
| Negative                         | −0.411| 0.172 | 5.735   | 0.017  | 0.66  | 0.47–0.93       |
| Ki-67 status                     |       |       |         |         |       |                 |
| Positive                         | 1.00  |       |         |         |       |                 |
| Negative                         | 0.522 | 0.176 | 8.791   | 0.003  | 1.69  | 1.19–2.38       |
| Surgery for BC                   |       |       |         |         |       |                 |
| Yes                              | 1.00  |       |         |         |       |                 |
| No                               | 1.372 | 0.181 | 57.553  | <0.001 | 3.94  | 2.77–5.62       |
| Chemotherapy                     |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.802| 0.344 | 5.430   | 0.020  | 0.45  | 0.23–0.88       |
| Radiotherapy                     |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.036| 0.150 | 0.058   | 0.810  | 0.97  | 0.72–1.30       |
| Endocrinotherapy                 |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.473| 0.147 | 10.35   | 0.001  | 0.62  | 0.47–0.83       |
| Targeted therapy                 |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | 0.211 | 0.211 | 0.998   | 0.318  | 1.24  | 0.82–1.87       |
| Time of BM                       |       |       |         |         |       |                 |
| SBM                              | −1.104| 0.163 | 45.613  | <0.001 | 0.33  | 0.24–0.46       |
| MBM                              |       |       |         |         |       |                 |
| Radiotherapy for BM              |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | 0.085 | 0.186 | 0.208   | 0.649  | 1.09  | 0.76–1.57       |
| Pathological fracture            |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | 0.300 | 0.263 | 1.304   | 0.254  | 1.35  | 0.81–2.26       |
| Spinal cord compression          |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.066| 0.416 | 0.026   | 0.873  | 0.94  | 0.41–2.11       |
| Surgery for BM                   |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | 0.077 | 0.455 | 0.029   | 0.865  | 1.08  | 0.44–2.63       |
| Performance of BPs               |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.382| 0.166 | 5.288   | 0.021  | 0.68  | 0.49–0.95       |
| Liver metastasis                 |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | 0.469 | 0.147 | 10.140  | 0.001  | 1.60  | 1.2–2.13        |
| Brain metastasis                 |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | 0.355 | 0.212 | 2.807   | 0.094  | 1.43  | 0.94–2.16       |
| Lung metastasis                  |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.311| 0.150 | 4.335   | 0.037  | 0.73  | 0.55–0.98       |
| Other organs metastasis          |       |       |         |         |       |                 |
| No                               | 1.00  |       |         |         |       |                 |
| Yes                              | −0.366| 0.179 | 4.182   | 0.041  | 0.69  | 0.49–0.99       |

HGB: hemoglobin; CA153: carbohydrate antigen 153; CEA: carcinoembryonic antigen; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.
### Table 3: Multivariate Cox proportional hazard regression model for analyzing the independent prognostic factors in the construction cohort.

| Subject characteristics | B     | SE   | Wald | P value | HR   | HR 95% CI      |
|-------------------------|-------|------|------|---------|------|----------------|
| **Age**                 |       |      |      |         |      |                |
| 18–45                   | 0.087 | 0.192| 0.206| 0.650   | 1.09 | 0.75–1.59      |
| 46–55                   | −0.023| 0.224| 0.010| 0.918   | 0.98 | 0.63–1.52      |
| >55                     |       |      |      |         |      |                |
| **ABO blood type**      |       |      |      |         |      |                |
| A type                  | 0.315 | 0.204| 2.376| 0.123   | 1.37 | 0.92–2.04      |
| B type                  | 0.495 | 0.265| 3.503| 0.061   | 1.64 | 0.98–2.76      |
| AB type                 | 0.047 | 0.231| 0.042| 0.837   | 1.05 | 0.67–1.65      |
| O type                  |       |      |      |         |      |                |
| **CA153**               |       |      |      |         |      |                |
| 0–25 U/ml               | −0.268| 0.189| 2.005| 0.157   | 0.77 | 0.53–1.11      |
| >25 U/ml                |       |      |      |         |      |                |
| **ALP**                 |       |      |      |         |      |                |
| 50–135 U/L              |       |      |      |         |      |                |
| <50 U/L                 | 0.090 | 0.290| 0.097| 0.756   | 1.09 | 0.62–1.93      |
| >135 U/L                | 0.536 | 0.197| 7.448| 0.006   | 1.71 | 1.16–2.51      |
| **Grade**               |       |      |      |         |      |                |
| I-II                    | 0.124 | 0.197| 0.392| 0.531   | 1.13 | 0.77–1.67      |
| III                     |       |      |      |         |      |                |
| **Lymph node metastasis**|       |      |      |         |      |                |
| Yes                     | −0.075| 0.209| 0.129| 0.719   | 0.93 | 0.62–1.40      |
| No                      |       |      |      |         |      |                |
| **ER status**           |       |      |      |         |      |                |
| Positive                | −0.066| 0.214| 0.094| 0.759   | 0.94 | 0.62–1.42      |
| Negative                | 0.289 | 0.191| 2.303| 0.129   | 1.34 | 0.92–1.94      |
| **PR status**           |       |      |      |         |      |                |
| Positive                | 0.341 | 0.207| 2.714| 0.099   | 1.41 | 0.94–2.11      |
| Negative                | −0.207| 0.197| 1.106| 0.293   | 0.81 | 0.55–1.20      |
| **Her-2 status**        |       |      |      |         |      |                |
| Positive                | 0.786 | 0.267| 8.655| 0.003   | 2.19 | 1.30–3.70      |
| Negative                | −0.373| 0.406| 0.845| 0.358   | 0.69 | 0.31–1.53      |
| **Surgery for BC**      |       |      |      |         |      |                |
| Yes                     | 0.684 | 0.247| 7.646| 0.006   | 1.98 | 1.22–3.22      |
| No                      | −0.080| 0.190| 0.178| 0.673   | 0.92 | 0.64–1.34      |
| **Chemotherapy**        |       |      |      |         |      |                |
| No                      |       |      |      |         |      |                |
| Yes                     | −0.308| 0.200| 2.364| 0.124   | 0.74 | 0.50–1.09      |
| **Endocrinotherapy**    |       |      |      |         |      |                |
| No                      |       |      |      |         |      |                |
| Yes                     | −0.216| 0.165| 1.725| 0.189   | 0.81 | 0.58–1.11      |
| **Time of BM**          |       |      |      |         |      |                |
| MBM                     | 0.521 | 0.175| 8.872| 0.003   | 1.68 | 1.20–2.37      |
| SBM                     |       |      |      |         |      |                |
| **Performance of BPs**  |       |      |      |         |      |                |
| No                      |       |      |      |         |      |                |
| Yes                     | −0.080| 0.190| 0.178| 0.673   | 0.92 | 0.64–1.34      |
| **Liver metastasis**    |       |      |      |         |      |                |
| No                      |       |      |      |         |      |                |
| Yes                     | 0.521 | 0.175| 8.872| 0.003   | 1.68 | 1.20–2.37      |
| **Lung metastasis**     |       |      |      |         |      |                |
| No                      |       |      |      |         |      |                |
| Yes                     | −0.216| 0.165| 1.725| 0.189   | 0.81 | 0.58–1.11      |
As one of the biochemical bone markers, ALP indicated tumor burden and distant metastasis [24]. Consistent with previous studies, elevated ALP was an independent prognostic factor in the present study [23, 25]. Patients with elevated ALP were at 1.71-fold risk of death compared with those with normal ALP. In a retrospective study focusing on bone-only metastasis patients, the median OS were 31.0 and 15.0 months for patients with normal and elevated serum ALP (\(P < 0.002\)) [22]. Better median OS (48.0 months) was suggested among patients with elevated ALP in the present study, which may be attributed to the high proportion of MBM patients.

In recent years, the definition of BM (SBM/MBM) was a global concern in distant metastasis [26, 27]. Sufficient evidence showed the significant difference between SBM and MBM in clinicopathologic characteristics and survival outcome [21, 26, 28]. However, SBM and MBM were still not well defined, which might be the main reason for inconsistent conclusions in previous studies [26, 27]. Although five characteristics (including age at diagnosis, ER status, PR status, Her-2 status, and the performance of BPs) were not independent prognostic factors in the present study, they were integrated in the nomogram after considering their significant effects on prognosis in literatures [6, 29, 30].

Several nomograms were constructed based on SEER database to predict the prognosis of MBC patients at diagnosis [18, 19]. A retrospective study comprising 5,860 BCBM patients reported prognostic nomograms to predict overall survival (OS) and cancer-specific survival (CSS) [19]. The C-index of OS and CSS in the construction cohort was 0.705 and 0.710, respectively. Calibration plots showed the prediction curves were close to 45 degrees in two models [19]. Another SEER-based study enrolled 7,199 stage IV BC patients to predict 1-year and 3-year OS rates, which can stratify patients into different risk groups for clinic demands [18]. These two nomograms were well established and presented good discrimination and calibration. However, due to the limitation of SEER database, the patients with MBM were not involved. Thus, the models cannot be widely used in clinic. At the same time, seldom Chinese patients were recorded; considering racial disparity in cancer, a cohort based on Chinese population is needed.

The present study had some limitations. First, as with many retrospective studies, there was inherent selection bias that cannot be assessed or avoided. Second, missing data were completed by statistical methods, which may lead to the reduction of sample’s representativeness. Last but not least, limited Department of Bone and Soft Tissue Tumor was established in China; only internal validation was

| Subject characteristics | B     | SE    | Wald | \(P\) value | HR  | HR 95% CI |
|------------------------|-------|-------|------|-------------|-----|-----------|
| Other organs metastasis| No    |       |      |             | 1.00|           |
|                        | Yes   | −0.288| 0.197| 2.139       | 0.144| 0.75      |
| CA153: carbohydrate antigen 153; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.|

**Points**

| Points | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|--------|---|---|---|---|---|---|---|---|---|---|----|
| Age at diagnosis | ≤45 | 46-55 | >55 |
| ER | Positive | Negative |
| PR | Positive | Negative |
| Her-2 | Negative | Positive |
| ALP | ≤50 | 50-135 U/L | >135 U/L |
| Surgery | Yes | No |
| Bone metastasis | Metachronous | Synchronous |
| Liver metastasis | Yes | No |
| Bisphosphonates drug | Yes | No |
| Total Points | 0 | 5 | 10 | 15 | 20 | 25 | 30 | 35 | 40 | 45 | 50 |
| 1-year survival | 0.95 | 0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.05 |
| 3-year survival | 0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.05 | 0.01 |
| 5-year survival | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.05 | 0.01 | 0.001 |
| 10-year survival | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.05 | 0.01 | 0.001 | 0.001 |

**Figure 3:** The nomogram to predict survival outcomes for breast cancer patients with bone metastasis.
Figure 4: The ROC curves to predict 1-year, 3-year, 5-year, and 10-year survival in construction cohort.

Figure 5: The calibration curves in construction cohort.
Figure 6: The ROC curves to predict 1-year, 3-year, 5-year, and 10-year survival in validation cohort.

Figure 7: The calibration curves in validation cohort.
References

1. R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.
2. N. Pashayan, A. C. Antoniou, U. Ivanus et al., “Personalized early detection and prevention of breast cancer: ENVISION consensus statement,” Nature Reviews Clinical Oncology, vol. 17, no. 11, pp. 687–705, 2020.
3. J. S. Cardoso, W. Silva, and M. J. Cardoso, “Evolution, current challenges, and future possibilities in the objective assessment of aesthetic outcome of breast cancer locoregional treatment,” The Breast, vol. 49, pp. 123–130, 2020.
4. J. A. Malmgren, G. S. Calip, M. K. Atwood, M. Mayer, and H. G. Kaplan, “Metastatic breast cancer survival improvement restricted by regional disparity: surveillance, epidemiology, and end results and institutional analysis: 1990 to 2011,” Cancer, vol. 126, no. 2, pp. 390–399, 2020.
5. N. Niikura, J. Liu, N. Hayashi et al., “Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis,” The Oncologist, vol. 16, no. 2, pp. 155–164, 2011.
6. S. G. Ahn, H. M. Lee, S.-H. Cho et al., “Prognostic factors for patients with bone-only metastasis in breast cancer,” Yonsei Medical Journal, vol. 54, no. 5, p. 1168, 2013.
7. R. P. Piggott, P. S. Waters, and M. J. Kerin, “The influence of breast cancer subtype on bone metastases development and survival in women with metastatic breast cancer,” Irish Journal of Medical Science, vol. 186, pp. 97–102, 2017.
8. X. Li, X. Zhang, J. Liu, and Y. Shen, “Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study,” BMC Cancer, vol. 20, 2020.
9. C. Zhao, Z. Zhang, N. Zhong et al., “Outcomes and prognostic factors for surgically treated patients with breast cancer spine metastases,” Journal of Bone Oncology, vol. 12, pp. 38–43, 2018.
10. A. Parkes, C. L. Warneke, K. Clifton et al., “Prognostic factors in patients with metastatic breast cancer with bone-only metastases,” The Oncologist, vol. 23, no. 11, pp. 1282–1288, 2018.
11. K. Cetin, C. F. Christiansen, C. Sværke, J. B. Jacobsen, and H. T. Sørensen, “Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval,” BMJ Open, vol. 5, Article ID e007702, 2015.
12. R. Foerster, T. Bruckner, T. Bostel, J. Schlampp, J. Debus, and H. Rief, “Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer,” Radiation Oncology, vol. 10, no. 1, p. 144, 2015.
13. Y.-H. Lee, H. Bang, and D. J. Kim, “How to establish clinical prediction models,” Endocrinology and Metabolism, vol. 31, no. 1, pp. 38–44, 2016.
14. G. S. Collins, J. B. Reitsma, D. G. Altman, and K. G. M. Moons, “Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement,” BMJ, vol. 350, p. g7594, 2015.
15. C. Zhang, M. Mao, X. Guo et al., “Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer,” BMC Cancer, vol. 19, no. 1, p. 238, 2019.
16. X. Wang, M. Mao, G. Xu et al., “The incidence, associated factors, and predictive nomogram for early death in stage IV colorectal cancer,” International Journal of Colorectal Disease, vol. 34, no. 7, pp. 1189–1201, 2019.
17. Y. Xu, G. Xu, H. Wu et al., “The nomogram for early death in patients with bone and soft tissue tumors,” Journal of Cancer, vol. 11, no. 18, pp. 5359–5370, 2020.
18. S. Li, J. Zhao, L. Zhu, F. Su, and K. Chen, “Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients,” Cancer Medicine, vol. 6, no. 11, pp. 2586–2594, 2017.
19. Z. Wang, Y. Cheng, S. Chen et al., “Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation,” Annals of Translational Medicine, vol. 8, no. 5, p. 197, 2020.
20. S. Turanli, “The role of surgery in breast cancer patients with isolated bone metastases at the time of diagnosis,” Journal of Surgical Oncology, vol. 100, no. 2, pp. 95–99, 2009.
21. S. Turanli, “Importance of the development time of isolated bone metastasis in breast cancer,” Langenbeck’s Archives of Surgery, vol. 397, no. 6, pp. 967–972, 2012.
22. C. Nieder, A. Dalhaug, A. Pawinski, B. Mannsäker, and E. Haukland, “Survival after palliative radiotherapy in patients with breast cancer and bone-only metastases,” In Vivo, vol. 30, no. 6, pp. 879–884, 2016.
[23] B. Chen, D. Dai, H. Tang et al., “Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer,” *Journal of Cancer*, vol. 7, no. 15, pp. 2309–2316, 2016.

[24] W. X. Du, S. F. Duan, J. J. Chen, J. F. Huang, L. M. Yin, and P. J. Tong, “Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis,” *Journal of Cancer Research and Therapeutics*, vol. 10, pp. C140–C143, 2014.

[25] P. S. Blanchette, D. N. Desautels, G. R. Pond et al., “Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab,” *Breast Cancer Research and Treatment*, vol. 170, no. 1, pp. 169–177, 2018.

[26] C.-X. Ma, X. Guan, R. Wei et al., “The distinction of clinicopathological characteristics, treatment strategy and outcome in colorectal cancer patients with synchronous vs. metachronous bone metastasis,” *Frontiers in Oncology*, vol. 10, p. 974, 2020.

[27] J. Mikami, Y. Kimura, Y. Makari et al., “Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis,” *World Journal of Surgical Oncology*, vol. 15, no. 1, p. 8, 2017.

[28] W. Ma, X. Wang, G. Xu et al., “Distant metastasis prediction via a multi-feature fusion model in breast cancer,” *Aging*, vol. 12, no. 18, pp. 18151–18162, 2020.

[29] A. Purushotham, E. Shamil, M. Cariati et al., “Age at diagnosis and distant metastasis in breast cancer—a surprising inverse relationship,” *European Journal of Cancer*, vol. 50, no. 10, pp. 1697–1705, 2014.

[30] A. Yazdani, S. Dorri, A. Atashi, H. Shirafkan, and H. Zabolinezhad, “Bone metastasis prognostic factors in breast cancer,” *Breast Cancer: Basic and Clinical Research*, vol. 13, Article ID 1178223419830978, 2019.